Barclays
SEEL

Barclays’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Barclays’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4
Closed -$13K – 5330
2022
Q1 		$13K Sell
4
-27
-87% -$116K ﹤0.01% 4554
2021
Q4 		$195K Buy
31
+21
+210% +$161K ﹤0.01% 3577
2021
Q3 		$97K Sell
10
-6
-38% -$51.6K ﹤0.01% 3913
2021
Q2 		$157K Buy
+16
New +$263K ﹤0.01% 3652
2021
Q1 		– Hold
0
– – – 4490
2020
Q3 		– Hold
0
– – – 5670
2020
Q2 		– Hold
0
– – – 6376
2020
Q1 		– Hold
0
– – – 6544
2019
Q4 		– Hold
0
– – – 6910

Other funds holding SEEL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's SEEL Position: Q2 2022 in Review

Barclays sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q2 2022, closing a stake of 4 shares — an estimated $13K sold.

Barclays first reported a position in SEEL in Q2 2021 and held it in 4 quarters. The position peaked at $195K in Q4 2021. 65 funds tracked by Wall St. Rank hold SEEL as of Q2 2022.

  • Barclays reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Barclays sold 4 Seelos Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $13K.
  • Barclays first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • Barclays's Seelos Therapeutics, Inc. Common Stock position peaked at $195K in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.